Herein, we present evidence from proof-of-principle studies that selective inhibition of a single molecular target, SCFβ-TrCP/FWD1, upstream of the proteasome in myeloma cells mimics the anti-tumor effect of proteasome inhibition. Here, BTRC is linked to plasma cell myeloma.